Highlights

  • Control Bionics shares rose 18.64% to AUD 0.070 during the afternoon session on 4 June 2026.
  • The company highlighted progress across its Assistive Technology, NeuroTech Solutions, and Platform & Medical Technologies divisions.
  • The company received a US$100,000 advance payment under a Letter of Intent contemplating 1,000 iOS-based speech-generating devices over 12 months.
  • Distribution rollout continues through Tobii Dynavox and PRC-Saltillo, with broader sales activation expected during 2026.

Control Bionics Ltd (ASX:CBL) shares climbed 18.64% to AUD 0.070 during the afternoon session on 4 June 2026 after the company released an update detailing progress across its commercial operations, customer relationships and technology deployment initiatives. The stock has also delivered a gain of 133.33% over the past year, reflecting growing investor attention toward the company's efforts to broaden the commercial applications of its neural-signal technology platform.

The latest update outlined developments across Control Bionics' three strategic pillars—Assistive Technology, NeuroTech Solutions, and Platform & Medical Technologies—with management highlighting increased customer engagement, distribution expansion, reimbursement progress and a growing pipeline of partnerships across healthcare, rehabilitation, sport and research markets.

Control Bionics is a global neurotechnology company focused on commercialising non-invasive neural-signal technology. Its core platform captures electrical signals generated by muscles and converts them into actionable data that can be used across communication, rehabilitation, sports performance, research and emerging human-computer interface applications. The company's flagship technologies include NeuroNode and NeuroStrip, both of which are based on proprietary surface electromyography (sEMG) capabilities.

Assistive Technology Continues to Provide Commercial Foundation

The Assistive Technology division remains the company's primary commercial base, with NeuroNode continuing to serve individuals with complex communication and physical challenges.

A key milestone highlighted in the update was the ongoing impact of the dedicated E2513 HCPCS reimbursement code in the United States. According to the company, US states representing almost 70% of the country's population have now funded NeuroNode through the HCPCS pathway.

Funding activity has so far been supported by a combination of Medicare, commercial insurance and Medicaid. Claims activity is currently estimated to comprise approximately 55% Medicare, 35% commercial insurance and 10% Medicaid.

Management views the reimbursement pathway as an important development because it provides a more structured funding framework for NeuroNode adoption. The company believes this supports a transition away from a direct retail sales approach toward a broader wholesale distribution model that can potentially increase market reach.

Distribution Partnerships Begin Delivering Early Sales Activity

Control Bionics also reported progress with major distribution agreements signed in recent months.

Following the company's initial five-state agreement with Tobii Dynavox in the United States, onboarding and Training activities have now been completed, and the first funded sales have commenced. The current focus is on supporting customers and distribution teams during the early stages of implementation.

The company expects discussions with Tobii Dynavox during June 2026 regarding expansion into additional US states.

Another notable development involves PRC-Saltillo, with whom Control Bionics signed a nationwide US distribution agreement in January 2026. Funded sales have already begun under the arrangement, while broader activation across PRC-Saltillo's sales network is expected later this year.

The company noted that PRC-Saltillo's sales organisation includes approximately 70 sales representatives, with wider rollout activities anticipated during the latter part of the US summer.

These distribution relationships have the potential to significantly increase NeuroNode's exposure across the United States market through established partner-led sales channels.

New Product Opportunities and International Expansion Initiatives

Beyond existing product offerings, Control Bionics is also advancing new commercial opportunities.

In April 2026, the company signed a Letter of Intent with a launch customer for the Supply of iOS-based speech-generating devices. The agreement contemplates the delivery of 1,000 devices over the first 12 months and was accompanied by a US$100,000 advance payment.

Device shipments are expected to begin in July 2026.

Management indicated that the initiative is intended to broaden the company's product portfolio while strengthening its relevance among distributors seeking scalable communication solutions.

Control Bionics also entered a long-term supply agreement with the New York Board of Education for NeuroNode. The arrangement establishes a recognised purchasing pathway for the technology and is expected to support distribution partner activity within the education sector.

Outside the United States, the company reported progress in Germany, where NeuroNode received HMV insurance coverage during February 2026. This development creates a reimbursement pathway in one of Europe's key healthcare markets.

The company is currently in discussions with multiple potential distribution partners as it evaluates opportunities to expand NeuroNode's presence in Germany.

NeuroStrip Gains Momentum Across Sport and Rehabilitation Markets

A significant portion of the update focused on growing customer engagement for NeuroStrip, the company's wearable sEMG platform designed to capture muscle activation data in real-world environments.

Across Australia, Control Bionics is working with several sporting organisations to evaluate applications related to rehabilitation, athlete profiling and return-to-play decision-making.

Current engagements include trials with Sydney-based and Melbourne-based AFL clubs, a Queensland rugby league team, an Australian national governing body representing a major winter sport, and the Australian Institute of Sport.

The company is also conducting a three-month trial with Royal Rehab, which operates more than 50 locations across Australia. The project is assessing NeuroStrip's potential use across both clinical and at-home rehabilitation settings.

Management views these initiatives as important opportunities to validate the practical application of objective muscle activity data in both elite sporting and healthcare environments.

Growing International Interest Supports Broader Commercial Reach

Outside Australia, Control Bionics reported increasing international engagement.

The company disclosed that a team is currently in Europe working with a major football club that is actively exploring the use of sEMG technology across its operations.

Additional activity includes onboarding an international rugby federation during June and engagement with an international rugby league team focused on player readiness assessments and performance monitoring.

In the United States, several projects are progressing through academic and sporting institutions.

At Ohio University, projects include athlete concussion-related profiling involving more than 500 athletes, baseline sEMG assessments for up to approximately 100 members of the general population, and basketball-related performance applications.

The company is also collaborating with Weber State on profiling the entire women's volleyball team as part of broader efforts to expand NeuroStrip's use within collegiate sports environments.

Alongside these initiatives, NeuroBounce—Control Bionics' sports performance program combining sEMG feedback with targeted training protocols—continues to gain traction through relationships with Weber State, Hoops Hall, Club V South and Peak Performance.

Healthcare and Rehabilitation Partnerships Continue to Expand

Control Bionics is simultaneously advancing rehabilitation opportunities across several healthcare providers and research institutions.

Bay State Physical Therapy has begun rolling out NeuroStrip within its clinic network, which spans more than 160 locations across the United States.

The company also reported engagement with Mountain Land Physical Therapy, which operates approximately 70 clinics. A case study is currently progressing around the company's "Super Bridge" application.

According to Control Bionics, the program has demonstrated Revenue generation potential of between US$1,175 and US$1,375 per client, while participants have recorded improvements of between three and nine inches in jump height and increases of up to 15 inches in lateral jumping capability.

Further healthcare-related activity includes collaborations with Mayo Clinic and Penn State Health, where NeuroStrip is being evaluated for research and clinical applications.

In Japan, Control Bionics highlighted a rehabilitation case study conducted alongside Stroke Lab. The company reported that a patient recovering from a severe brain bleed experienced a reduction in gastrocnemius peak muscle activity from 163.9 microvolts to 99.8 microvolts, representing a 39% reduction in muscle overactivity.

The intervention also resulted in zero falls during post-treatment walking assessments, demonstrating potential rehabilitation applications for real-time EMG biofeedback technologies.

Platform Strategy Advances Through Apple Integration and Research Collaborations

The company's third strategic pillar, Platform and Medical Technologies, is focused on commercialising its neural-signal platform beyond existing hardware products.

A key initiative remains the planned integration of Apple's Brain Computer Interface (BCI) protocol.

Control Bionics stated that development work is underway, with integration expected to be included within the next generation of software targeted for commercial release during the third quarter of 2026.

Management believes the integration could improve customer experiences while potentially opening additional applications beyond traditional assistive technology markets.

The company also continues to engage with a growing network of research and academic institutions, including Mayo Clinic, Barrow Neurological Institute, Penn State Health, the University of Sydney, Victoria University, the University of Melbourne and ICCD Partners.

These relationships are intended to support ongoing validation of the technology platform while exploring new research, clinical and commercial opportunities.

What This Means for Investors

Control Bionics' latest update highlights continued commercial progress across multiple operating segments rather than reliance on a single market opportunity.

The announcement showcased expanding reimbursement coverage, early sales activity through major distribution partners, international market development, new product initiatives and a growing number of sports, rehabilitation and research engagements.

Investors appeared to respond favourably to the update, with the share price rising during Thursday's session as the company outlined additional pathways for commercial adoption of its neural-signal technology platform. While many initiatives remain in trial, rollout or Partnership phases, the update demonstrated increasing customer activity across several geographic regions and end markets, supporting the company's strategy of deploying a single technology platform across multiple commercial applications.